💉 mRNA Vaccine Pilot Plant

Модуль #314. Pilot mRNA Vaccine Plant Almaty/Astana — план посткованая капасити для emergency response (BioNTech / Moderna model). Reference: BioNTech Marburg 1B doses/year, Moderna Norwood Massachusetts 600M doses, Pfizer Puurs Belgium 4B/year. Process: linearized plasmid template + IVT in-vitro transcription (T7 RNA polymerase + NTPs) → mRNA + Cap analog ARCA + 5-mC + pseudouridine modified → LNP Lipid Nanoparticle encapsulation (4 lipids ALC-0315/ALC-0159/cholesterol/DSPC) → fill-finish sterile vials. Capacity 10M doses/year pilot. EU GMP Annex 1 + FDA + ICH Q5/Q6 + СН РК 3.02-19.

1. Состав mRNA pilot 10M doses/year

Plasmid DNA production — E.coli fermentation 100 L Sartorius + lysis Roche + alkaline purification + DNase + linearisation with restriction enzyme;
IVT in-vitro transcription bioreactor 50 L — T7 RNA polymerase + NTPs (ATP/UTP/CTP/GTP + ARCA cap) + DNA template + buffer, 37 °C × 4 hr;
mRNA modification — pseudouridine + 5-methylcytidine для immune evasion + stability (Karikó/Weissman 2005 Nobel Prize 2023);
mRNA purification — DNase digestion + chromatography Cytiva Capto Core 700 + Oligo dT для poly-A capture + TFF Pall Pellicon 50 м²;
LNP Lipid Nanoparticle formulation — microfluidic mixer Precision NanoSystems NanoAssemblr Ignite, mRNA + ethanol-dissolved lipids → 80-100 nm particles dynamic light scattering DLS confirmation;
Lipid components — ALC-0315 ionisable + ALC-0159 PEG-lipid + cholesterol + DSPC (Pfizer recipe); или SM-102 + PEG-DMG (Moderna);
Buffer exchange — TFF Diafiltration removes ethanol + buffer exchange to formulation buffer (sucrose Tris saline);
Sterile filtration — 0.22 μm Millipore Express + dual-stage 0.45+0.22 redundant;
Fill-finish — aseptic vial filling line Optima Pharma 200 vials/min, freeze-thaw stability storage -80 °C ULT;
Lyophilisation Telstar LyoBeta для freeze-dried стабильность 2-8 °C (vs frozen -80 °C);
QC lab — HPLC reverse-phase Agilent для mRNA integrity + RT-qPCR для intactness + DLS Malvern для LNP size + endotoxin LAL Charles River;
Cleanroom suite ISO 14644 cl.5+7 + EU GMP Annex 1 grade A/B/C/D, 2000 m² total;
Cold chain -80 °C ULT × 30 для bulk storage + -20 °C distribution + 2-8 °C lyo;
Regulatory team — FDA BLA + EU EMA Marketing Authorisation + WHO PreQ submission;
Cybersecurity 21 CFR Part 11 + data integrity ALCOA+ + electronic batch records SAP S/4HANA.

Упражнение 1 — Why mRNA platform

Только дешёвый ingredientТолько быстрая разработкаТолько COVID-specificmRNA technology advantages per Nature Reviews Drug Discovery + BioNTech/Moderna: (1) rapid design — antigen sequence → mRNA synthesis 1-2 weeks vs traditional protein vaccine 6-12 months; (2) platform technology — same manufacturing process для any pathogen, only sequence changes (Pfizer pivoted COVID-2 vaccine в недели); (3) no cell culture — IVT enzymatic synthesis cell-free, scalable 1 L → 200 L without traditional bioreactor scale-up issues; (4) no infectious viral material in manufacturing (vs traditional inactivated vaccine); (5) self-amplifying mRNA saRNA Variant gives 10-100x dose reduction; (6) cancer therapeutic mRNA Cancer Immunotherapy CIT trials Moderna mRNA-4157 personalised neoantigen tumor vaccine; (7) other diseases — influenza universal vaccine, RSV maternal protect newborn, herpes simplex genital infection; (8) emerging — therapeutic protein replacement therapy CFTR cystic fibrosis through mRNA; (9) limitations — cold chain logistics challenging (-80 °C BioNTech, -20 °C Moderna), shelf life shorter; (10) pricing — $20-40 per dose (vs $5-10 traditional inactivated). Nature Rev Drug Discovery + BioNTech/Moderna scientific publications + FDA EUA + EU EMA CHMP

Упражнение 2 — Doses per year

Упражнение 3 — Капекс mRNA pilot

Cleanroom suite ISO 14644 cl.5 + GMP Annex 1 (2000 m²) = 10 млрд
IVT bioreactor 50 L + downstream chromatography Cytiva = 6 млрд
LNP formulation Precision NanoSystems NanoAssemblr Ignite = 4 млрд
Fill-finish Optima Pharma aseptic + lyophilizer Telstar = 5 млрд
QC lab — HPLC Agilent + DLS Malvern + LAL + RT-qPCR = 2.5 млрд
Cold chain -80 °C ULT × 30 + -20 °C distribution = 1.5 млрд
Validation + проектирование 5% + EU GMP audit + insurance = 3 млрд

Упражнение 4 — Cold chain

Просто холодильник 4 °CТолько домашняя заморозка -20 °CMulti-tier cold chain per WHO PQS + BioNTech Distribution Manual: (1) ULT -80 °C BioNTech original — Pfizer Thermal Shipper dry ice 5 days holding + GPS tracking; -80 °C ULT freezer Thermo TSX Series 30 days at distribution centre; (2) -20 °C Moderna — domestic medical freezer 30-day stability; (3) 2-8 °C refrigerator — 5-day stability (BioNTech) или 30-day (Moderna lyophilised version); (4) freezing damage — LNP membrane disruption if slow thaw, multiple freeze-thaw cycles degrade mRNA; (5) lyophilisation Telstar или CSU Universa freeze-dryer removes water → product stable at 2-8 °C for 18-24 months (vs frozen 6-12 months); (6) sub-zero distribution — Pfizer Thermal Shipper insulated foam + dry ice; PCM phase change material containers EcoCool; (7) tracking — Sensitech digital data loggers RFID + GPS continuous T+humidity monitoring, alarm at deviation; (8) WHO Prequalification PQ для emerging markets requires 2-8 °C stability (lyo form preferred); WHO PQS + BioNTech Cold Chain Manual + USP <659> + ICH Q1A/Q1B + ASHRAE Pharmaceutical Refrigeration GuidelinesВ обычной комнатной температуре

Нормативная база

EU GMP Annex 1 (2022)
FDA 21 CFR 600/610 — Biologics
ICH Q5A/Q5B/Q5C/Q5D/Q5E/Q6B + Q1A/Q1B Stability
WHO Prequalification PQS
USP <1043> / <659> — Ancillary Materials / Refrigerator Standards
ISPE Baseline Biomanufacturing
ASHRAE Pharmaceutical Refrigeration Guidelines
СН РК 3.02-19 — Лечебно-проф. учреждения